Sixteen patients who were receiving placebo received sunitinib at the time of disease progression , with the best responses being @ partial response ( @ % ) , @ cases of stable disease ( @ % ) , and @ cases of progressive disease ( @ % ) ; @ patients were not evaluable for response .